BioForward Member, Horizon Therapeutics, announced that they will be teaming up with Q32 Bio to develop ADX-914 for the treatment of autoimmune diseases.

Horizon Therapeutics applies extensive research experience to target, design and execute R&D programs that explore the connections between science and disease states to both develop and deliver breakthrough treatments that will have a profound impact on underserved patients who don’t have many, if any, options.

Q32 Bio is a biotechnology company that specializes in therapies that restore immune homeostasis.

Read more about their project in this article.